Disclosed herein is a selective delivery molecule comprising: (a) an acidic sequence (portion A) which is effective to inhibit or prevent the uptake into cells or tissue retention, (b) a molecular transport or tissue retention sequence (portion B), and (c) a linker between portion A and portion B, and (d) cargo moieties (portion D.sub.A and D.sub.B).

In one aspect, the invention relates to polymers, crosslinked polymers, functionalized polymers, nanoparticles, and functionalized nanoparticles and methods of making and using same. In one aspect, the invention relates to degradable polymers and degradable nanoparticles. In one aspect, the invention relates to methods of preparing degradable nanoparticles and, more specifically, methods of controlling particle size during the preparation of degradable nanoparticles. In one aspect, the degradable nanoparticles are useful for complexing, delivering, and releasing payloads, including pharmaceutically active payloads. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The present invention relates to a peptide comprising an amino acid sequence at least 85% identical to the amino acid sequence as shown in SEQ ID NO. 1, wherein the residues Lys.sup.905, Arg.sup.909, and Arg.sup.912 contained therein are present, for use as a medicament, in particular for its use as an inhibitor of FGF-2 induced angiogenesis.

A phthalocyanine compound or targeted conjugate thereof having the formula (I).

Described herein are peptides and variants thereof as well as peptide constructs comprising peptides conjugated to, linked to, or fused to agents, wherein the peptides and peptide constructs are capable of binding TfR. Binding of a peptide or peptide construct as described herein to TfR can enable transcytosis across an endothelial layer, e.g., the blood brain barrier, or the crossing of a cell membrane. Pharmaceutical compositions and uses of peptides and peptide constructs, as well as methods of designing and manufacturing such peptides and peptide constructs, to treat a disease or condition are also described herein.

Targeted molecular imaging agents (TMIAs) are derived from coupling together pre-formed amino acids with imaging agents attached to their side chains. These peptide-based imaging agents may be synthesized from a single or multiple preformed amino acids containing multi-modal, multi-chelated metal, multi-dye imaging agents, or combinations of these, on the side chains of resultant peptides. These imaging amino acids or peptides may be conjugated directly, or activated, or attached to linkers to which targeting groups, such as peptides, proteins, antibodies, aptamers, or small molecule inhibitors, may be conjugated in the final steps of the synthesis to form a wide variety of TMIAs.

The present invention is directed to EGFR-specific peptide reagents, methods for detecting pre-cancer, early cancer and/or cancer using the peptide reagents, and methods for targeting pre-cancer cells, early cancer cells and/or cancer cells using the peptide reagents. In one aspect, the disclosure provides reagents consisting essentially of a peptide QRHKPRE (SEQ ID NO: 1), HAHRSWS (SEQ ID NO: 2), YLTMPTP (SEQ ID NO: 3), TYPISFM (SEQ ID NO: 4), KLPGWSG (SEQ ID NO: 5), IQSPHFF (SEQ ID NO: 6), YSIPKSS (SEQ ID NO: 7), SHRNRPRNTQPS (SEQ ID NO: 8), NRHKPREKTFTD (SEQ ID NO: 9).

The present invention provides turn-ON dioxetane-based chemiluminescence probes based on the Schapp's adamantylidene-dioxetane probe, which emit light in the near-infrared (NIR) region and are therefore useful for in vivo imaging, as well as compositions and uses thereof.

The present disclosure provides an isolated, engineered or non-naturally occurring protein comprising an antibody light chain variable domain (V.sub.L) which may comprise at least one negatively charged amino acid positioned between residues 49 to 56 according to the numbering system of Kabat, the protein capable of binding specifically to an antigen.

Compositions and articles comprising diamond particles, such as nanodiamond based pharmaceutical compositions, are generally provided. In some embodiments, the articles and methods comprising (nano)diamond particles may be useful for monitoring and/or treating a disease (e.g., in a subject).